1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,135 | 0,287 | 13:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.25 | AcouSort AB: AcouSort and MFX enter a collaboration to streamline future cell therapy manufacturing | 1.015 | GlobeNewswire (Europe) | AcouSort AB today announced it has entered a collaboration with MFX, a UK-based developer of next-generation scalable bioreactor platforms, to evaluate if AcouSort's technology can be paired with MFX's... ► Artikel lesen | |
| 15.12.25 | AcouSort AB: Stefan Blomsterberg elected new Chairman of the Board of AcouSort | 142 | GlobeNewswire (Europe) | AcouSort AB today announced that Stefan Blomsterberg has been appointed new Chairman of the Board, effective January 1, 2026.
Stefan Blomsterberg currently holds the position as CEO of CELLINK Bioprinting... ► Artikel lesen | |
| 26.11.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - September 2025 | 131 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
July - September 2025 for the GroupNet sales amounted to TSEK 1,248 (1,198)Result before tax... ► Artikel lesen | |
| 19.11.25 | AcouSort AB: AcouSort and Danish SeeQ Diagnostics sign technology evaluation agreement | 190 | GlobeNewswire (Europe) | AcouSort AB today announced it has signed a technology evaluation agreement with the Danish diagnostics company SeeQ Diagnostics concerning the evaluation of AcouSort's blood/plasma separation technology... ► Artikel lesen | |
| ACOUSORT Aktie jetzt für 0€ handeln | |||||
| 22.09.25 | AcouSort AB: AcouSort receives new order boosting Central European collaboration | 154 | GlobeNewswire (Europe) | AcouSort AB today announced it has received a third order from a Central European company that develops diagnostic systems and medical devices. The company evaluates AcouSort's novel technology for... ► Artikel lesen | |
| 27.08.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - June 2025 | 123 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
April - June 2025 for the GroupNet sales amounted to TSEK 1,551 (961)Result before tax amounted... ► Artikel lesen | |
| 28.05.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2025 | 253 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2025 for the GroupNet sales amounted to TSEK 1,595 (1,357)Result before tax amounted... ► Artikel lesen | |
| 09.04.25 | AcouSort AB: Bulletin from the Extraordinary General Meeting of AcouSort AB (publ) | 188 | GlobeNewswire (Europe) | The following resolutions were passed at the Extraordinary General Meeting (the "EGM") of AcouSort AB (publ) (the "Company") on 9 April 2025 in Lund.
Rights issue of sharesThe EGM resolved to approve... ► Artikel lesen | |
| 09.04.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 264 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
| 26.03.25 | AcouSort AB: AcouSort's CEO answers questions about the company's rights issue and gives his view on the future | 280 | GlobeNewswire (Europe) | In connection with AcouSort's announcement of its plan to carry out a rights issue, several shareholders have contacted the company with questions regarding both the issue itself and how the management... ► Artikel lesen | |
| 19.03.25 | AcouSort AB: AcouSort in new collaboration to improve sepsis treatment | 304 | GlobeNewswire (Europe) | AcouSort's business strategy relies on early development collaborations to integrate its separation technology in partnering companies' products and systems. The most recent collaboration of this kind... ► Artikel lesen | |
| 03.03.25 | AcouSort AB: AcouSort and Bio-ReCell enter collaboration | 249 | GlobeNewswire (Europe) | AcouSort AB ("AcouSort") and Bio-ReCell Ltd ("Bio-ReCell") announce that the two companies have signed a Letter of Intent to jointly explore developing a system for automated clean-up and isolation... ► Artikel lesen | |
| 14.02.25 | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2024 | 171 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037
Fourth quarter for the GroupNet sales amounted to TSEK 1,221 (0)Result before tax amounted to... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 51,50 | +0,04 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,392 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | ||
| SARTORIUS STEDIM BIOTECH | 177,75 | -0,42 % | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| BIOLIFE SOLUTIONS | 18,300 | -4,19 % | BioLife Solutions, Inc.: BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations | Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter
Full year unaudited revenue from continuing... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,420 | +3,01 % | ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? | ||
| CRESCENT BIOPHARMA | 7,200 | -3,36 % | Crescent Biopharma, Inc.: Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns |
ACOUSORT AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,124 Euro und damit -10,47 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACOUSORT AB finden Sie auf Wallstreet Online.